Item 7.01. Regulation FD Disclosure.

The Company on March 19, 2023 entered into a three-year $2,000,000 credit line facility, drawdowns under which bear interest at the rate of 7% per annum. The credit line does not permit conversion by the lender of amounts outstanding under the line into common stock. The credit line provides the Company with financing, through the FDA approval process and into commercial scale manufacturing, for the Company's patented lead product, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system.

See Press Release attached as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits





(d) Exhibits

The following exhibits are being filed with this Current Report on Form 8-K:

99.1 Nutriband Press Release dated March 28, 2023 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

© Edgar Online, source Glimpses